Longitude Capital
Mr. Diaz is a Venture Partner of Longitude Capital. Concurrently, Mr. Diaz serves as a Consultant for various companies in the healthcare industry, including Auven Therapeutics, where he previously served as Managing Director from 2008 to 2018. Prior to joining Auven Therapeutics, he was a Managing Member and co-founder of Diaz & Altschul Capital Management (D&A Capital). Prior to founding D&A Capital, Mr. Diaz was Managing Director and Head of the Healthcare group at Schroder Wertheim & Co. Mr. Diaz started his career at PaineWebber, where he was a key member of the PaineWebber Healthcare Investment Banking Group and President of PaineWebber Development Corporation. He currently sits on the board of Inozyme (INZY). Mr. Diaz holds an M.B.A. from Harvard Business School and a B.A. from Harvard University.
This person is not in any offices
Longitude Capital
Longitude Capital specializes in making venture growth investments in biotechnology, medical technology and health solutions companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. Longitude Capital invests in both privately held and publicly traded life science companies through a variety of investment approaches.